TD Cowen Lowers Astrana Health (NASDAQ:ASTH) Price Target to $35.00

Astrana Health (NASDAQ:ASTH) had its target price dropped by research analysts at TD Cowen from $40.00 to $35.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen’s price objective would suggest a potential upside of 47.06% from the stock’s current price.

A number of other analysts also recently commented on the company. BTIG Research lowered their target price on Astrana Health from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Zacks Research raised Astrana Health from a “strong sell” rating to a “hold” rating in a report on Friday, October 10th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Astrana Health in a research report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Astrana Health presently has a consensus rating of “Moderate Buy” and an average price target of $45.29.

Astrana Health Trading Up 6.1%

Shares of Astrana Health stock opened at $23.80 on Monday. The stock has a market cap of $1.33 billion, a PE ratio of 46.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.80. The firm has a fifty day moving average price of $30.09 and a 200 day moving average price of $27.78. Astrana Health has a 1 year low of $21.20 and a 1 year high of $46.74. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.59 and a quick ratio of 1.59.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Wednesday, January 10th. The company reported $0.50 EPS for the quarter. The company had revenue of $317.00 million for the quarter. Astrana Health had a net margin of 1.04% and a return on equity of 3.43%. Equities research analysts predict that Astrana Health will post 1.15 earnings per share for the current year.

Institutional Investors Weigh In On Astrana Health

A number of institutional investors have recently added to or reduced their stakes in ASTH. Covestor Ltd raised its position in Astrana Health by 777.6% during the first quarter. Covestor Ltd now owns 2,001 shares of the company’s stock worth $62,000 after acquiring an additional 1,773 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Astrana Health by 323.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $115,000 after purchasing an additional 3,517 shares during the period. AlphaQuest LLC increased its stake in shares of Astrana Health by 144.2% during the first quarter. AlphaQuest LLC now owns 4,883 shares of the company’s stock worth $151,000 after purchasing an additional 2,883 shares in the last quarter. State of Wyoming purchased a new stake in shares of Astrana Health during the second quarter worth about $132,000. Finally, US Bancorp DE raised its position in shares of Astrana Health by 21.3% during the 1st quarter. US Bancorp DE now owns 5,791 shares of the company’s stock worth $180,000 after purchasing an additional 1,015 shares during the last quarter. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.